DDInter150 DDInter1297
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Azathioprine {u} (Compound) resembles {v} (Compound) Adenine
Adenine {u} (Compound) resembles {v} (Compound) Tioguanine
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Niraparib
Azathioprine {u} (Compound) treats {v} (Disease) Crohn's disease
Crohn's disease {u} (Disease) is treated by {v} (Compound) Mercaptopurine
Mercaptopurine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is palliated by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Mercaptopurine
Mercaptopurine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine {u} (Compound) binds {v} (Gene) TPMT
TPMT {u} (Gene) is upregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Nucleic Acid Synthesis Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Azathioprine (Compound) resembles Adenine (Compound) and Adenine (Compound) resembles Tioguanine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azathioprine (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Niraparib
Azathioprine (Compound) treats Crohn's disease (Disease) and Crohn's disease (Disease) is treated by Mercaptopurine (Compound) and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azathioprine (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is palliated by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azathioprine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is bound by Mercaptopurine (Compound) and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azathioprine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azathioprine (Compound) binds TPMT (Gene) and TPMT (Gene) is upregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azathioprine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class) and Nucleic Acid Synthesis Inhibitors (Pharmacologic Class) includes Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib